Children's Hospital of Philadelphia leads or participates in hundreds of clinical trials. Use this database to learn the purpose of these trials, find out who can participate and more.
161 - 170 of 170
This study is arandomized, double-blind, placebo-controlled study that will evaluate thesafety and efficacy of dasiglucagon in children between the ages of 7 days and12 months who have congenital hyperinsulinism. Dasiglucagon will be given as asubcutaneous infusion while patients are admitted to the hospital. Othertreatments for hyperinsulinism may be changed as allowed while maintaining safeblood sugar levels. For the second part of the study, patients may be able togo home on the medication.
Congenital Hyperinsulinism is the most common cause of lowblood sugar (hypoglycemia) in infants and children. Infants who are born with this problem havelow blood sugar, which can cause seizures or brain damage.
We are doing this study to see if the patterns ofabnormalities in controlling insulin in children and adults withhyperinsulinism are related to any underlying genetic cause and to identifypossible new genetic causes. This willbe done by standard clinical tests of insulin control: a glucose tolerancetest, a protein tolerance test, and a fasting test.
This observational cohort study aims to estimate the rate of transmission of vaccine-strain rotavirus from vaccinated to unvaccinated infants during a one-year period in a U.S. NICU that routinely administers rotavirus vaccine to a large number of infants (>180 annually) who usually remain in the unit for a long period after receipt. The purpose of this study is to show how rotavirus vaccination can be given safely in the NICU setting.
Our team is working on a study to better understand neurological problems, including seizures and developmental delays, that occur in children with hyperinsulinism, including HI/HA syndrome, and type 1 diabetes mellitus. The study involves a one day visit to The Children’s Hospital of Philadelphia and The University of Pennsylvania for a specialized magnetic resonance imaging scan (MRI) of the brain, an electroencephalogram (EEG), blood draw, and completion of questionnaires to evaluate development and behavior. The entire study visit is expected to take about five hours. If you are interested in learning more, please contact us at HIResearch@email.chop.edu.
Inflammatory Bowel Disease (IBD) can sometimes add stress to your life and that may affect your physical symptoms of pain and stool habits. In this study, we want to know if practicing mindfulness via an online Mindfulness-based stress reduction (MBSR) course taught by a trained teacher can help with your IBD. If you are a patient with IBD, who is between 12-19 years of age, you might be eligible to participate in an 8 week long MBSR group course online. You will answer a series of questionnaires and submit stool samples 3 times over the course of the study, and you will also participate in 1 focus group to discuss your experience in the study. You will be compensated for your participation.
This study will recruit 400 participants to take ananonymous online survey about how police officers and people from the autismcommunity feel about interacting with each other. Individuals from theautism community will be taking a survey focused on understanding howindividuals with ASD and their parents feel about interacting with policeofficers. Policeofficers will take a survey focused on understanding how they feel aboutinteracting with individuals with autism spectrum disorder (ASD) while at work.Both surveys ask about police education and training centered around autism.The surveys take between 20 and 30 minutes and will be administered via REDCap.Interested participants will email the research coordinator who will ask themwhich survey they would like to complete. The research coordinator will thensend them a personal single-use link to complete the survey. Their email will onlybe used to provide compensation for their time ($20).
CHOP, in collaboration with Dana-Farber Cancer Institute, is conducting a study for children, adolescents, and young adults up to 31 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drugs ribociclib and everolimus to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.
CHOP, in collaboration with Janssen Research & Development, is conducting a study for children and young adults up to 30 years old, with relapsed or refractory precursor T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. This clinical trial is adding the study drug, daratumumab, to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT03384654". To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.
This study will evaluate the safety andtolerability of RGX-111 in patients with Mucopolysaccharidosis Type I with aneurocognitive deficit that are at least 4 months old. This study involvesadministration of the RGX-111, general anesthesia, lumbar puncture, blooddraws, MRI, ultrasound, electrocardiogram, echocardiogram, hearing test, andchart review. If you have questions or would like to learn more about thestudy, please contact the Principal Investigator, Dr. Ficicioglu at (215)590-3376.
The purpose of this study is to look at the safety and tolerability of RBX-121, a one-time gene therapy, in subjects with MPS II (Hunter Syndrome). You may be eligible for this study if you are a male between the ages of 4 months to 5 years old. Reimbursement for travel and research procedures will be provided. This study involves blood draws, interviews, urine collection, genetic testing, general anesthesia, lumbar punctures, MRI, gene therapy, lumbar puncture, ultrasound, ECG/echocardiogram and physical and neurological examinations. If you have questions or would like to learn more about the study, please contact the study team at MetabolismResearch@email.chop.edu.